頁籤選單縮合
題名 | 抗結核藥引起肝毒性之回顧=Review of Antituberculosis Drug-Induced Hepatotoxicity |
---|---|
作者姓名(中文) | 楊璦瑜; | 書刊名 | 藥學雜誌 |
卷期 | 32:2=127 2016.06[民105.06] |
頁次 | 頁51-56 |
分類號 | 418.2219 |
關鍵詞 | 結核病; 肝毒性; 抗結核藥引起肝毒性; Antituberculosis drug-induced hepatotoxicity; |
語文 | 中文(Chinese) |
中文摘要 | 結核病是全世界最致命的傳染病之一,然而第一線治療用藥常見有肝毒性,且 合併使用會增加肝毒性的風險。過去國外研究顯示使用抗結核藥產生肝毒性的發生 率約為2%-28%。抗結核藥物引起的肝毒性在亞洲人是比較嚴重的,發生的風險是歐 洲、非洲、加拿大的2.8倍。其他可能影響抗結核藥物產生肝毒性的因素包括高齡、 女性、營養不良、低白蛋白血症、慢乙醯化狀態、過去肝臟疾病。抗結核藥引起肝毒 性的機轉很多部份仍是未知的,且風險因子的研究未有一致之定論。本文藉由文獻回 顧探討相關機轉與潛在風險,提供醫療人員在使用抗結核病藥物治療過程作為參考依 據,以提升抗結核治療的安全性及完治率。 |
英文摘要 | Tuberculosis (TB) remains one of the world's deadliest communicable diseases. However, the first line treatment drugs, isoniazid (INH), pyrazinamide (PZA) and rifampicin (RMP), used in the regimen are potentially hepatotoxic and may lead to drug-associated hepatitis. The reported incidence of antituberculosis drug-induced hepatotoxicity, varies between 2% and 28%. The condition is more serious among asians, for whom the hepatotoxicity hazard ratio is reportedly around 2.8 compared to patients from Europe, Africa and Canada.Risk factors are advanced age, female sex, malnutrition, hypoalbuminemia, slow acetylator status and preexistent liver disease. The exact mechanism of antituberculosis drug-induced hepatotoxicity is unknown, variation in risk factor prevalence among different regions. This article will discuss the relationship between hepatotoxicity of each first-line anti-tuberculosis drug and risk factor to be able provide medical health team. To enhance the safety and complete cure rate of antituberculosis treatment. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。